Identification of a novel human doublecortin-domain-containing gene (DCDC1) expressed mainly in testis

Zeng, Li; Gu, Shaohua; Li, Yao; Zhao, Enpeng; Xu, Jian; Ye, Xin; Wu, Qiao; Wang, Liu; Xie, Yun; Mao, Yumin

doi:10.1007/s10038-003-0033-3

Cited by 36 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar strategy was used to analyze the metabolic effects of sequence variations in ANGPTL5 ( Figure 3A), a gene of unknown function that is not expressed in mice (13). A significant excess of NS variants was found in the lowest quartile of TG levels (n = 9) compared with the highest quartile (n = 1) (P = 0.022).…”

Section: Figurementioning

confidence: 99%

Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans

Romeo¹,

Wu²,

Kozlitina³

et al. 2008

J. Clin. Invest.

278

370

View full text Add to dashboard Cite

The relative activity of lipoprotein lipase (LPL) in different tissues controls the partitioning of lipoproteinderived fatty acids between sites of fat storage (adipose tissue) and oxidation (heart and skeletal muscle). Here we used a reverse genetic strategy to test the hypothesis that 4 angiopoietin-like proteins (ANGPTL3, -4, -5, and -6) play key roles in triglyceride (TG) metabolism in humans. We re-sequenced the coding regions of the genes encoding these proteins and identified multiple rare nonsynonymous (NS) sequence variations that were associated with low plasma TG levels but not with other metabolic phenotypes. Functional studies revealed that all mutant alleles of ANGPTL3 and ANGPTL4 that were associated with low plasma TG levels interfered either with the synthesis or secretion of the protein or with the ability of the ANGPTL protein to inhibit LPL. A total of 1% of the Dallas Heart Study population and 4% of those participants with a plasma TG in the lowest quartile had a rare loss-of-function mutation in ANGPTL3, ANGPTL4, or ANGPTL5. Thus, ANGPTL3, ANGPTL4, and ANGPTL5, but not ANGPTL6, play nonredundant roles in TG metabolism, and multiple alleles at these loci cumulatively contribute to variability in plasma TG levels in humans.

show abstract

Section: Figurementioning

confidence: 99%

Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans

Romeo¹,

Wu²,

Kozlitina³

et al. 2008

J. Clin. Invest.

278

370

View full text Add to dashboard Cite

show abstract

“…To this end, total human cord blood cells ( Figure 1A) were cultured in STIF medium containing Angptl5. 18 We seeded 2.5 ϫ 10 7 total cord blood cells at a density of 10 6 cells/mL medium. After 23 days of culture, the number of total cells in the presence of Angptl5 increased to 2.2 (Ϯ 0.3) ϫ 10 8 cells ( Figure 1A).…”

Section: Culture Of Total Human Cord Blood Cells In Serum-free Mediummentioning

confidence: 99%

Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation

Zhang

Kaba

Iizuka

et al. 2008

Blood

225

194

View full text Add to dashboard Cite

“…Thus, it is necessary to both understand the underlying molecular basis and develop effective preventive and therapeutic approaches. We and others have independently identified 7 angiopoietin-like proteins (Angptls), namely, Angptl1/angiopoietin-related protein 1 (ARP1)/angioarrestin, 1,2 Angptl2/ARP2, 3 Angptl3, 4,5 Angptl4/ARP4/PPARγ angiopoietin-related (PGAR)/fasting-induced adipose factor (FIAF)/hepatic fibrinogen/angiopoietin-related protein (HFARP), [6][7][8][9] Angptl5, 10,11 Angptl6/angiopoietin-like growth factor (AGF), 12 and Angptl7. 13 These Angptls are structurally similar to angiopoietins, which are characterized by a coiled-coil domain at the N-terminus and a fibrinogen-like domain at the C-terminus.…”

mentioning

confidence: 99%

Angiopoietin-Like Proteins Potential Therapeutic Targets for Metabolic Syndrome and Cardiovascular Disease

Oike

Tabata

2009

Circ J

View full text Add to dashboard Cite

Recent major increases in obesity and related metabolic diseases (known as the metabolic syndrome (MetS)) because of sedentary lifestyles and overnutrition in developed and developing countries, are an exploding medical and social problem. These conditions are associated with increased risk of cardiovascular disease (CVD), the leading cause of death. Thus, it is necessary to understand the molecular basis underlying MetS and develop effective preventive and therapeutic approaches against CVD. To date, 7 angiopoietin-like proteins (Angptls) that are structurally similar to angiopoietins have been identified. However, none binds to the angiopoietin receptor, Tie2, or to the closely related Tie1 receptor, suggesting that these ligands function differently from angiopoietins. Some Angptls potently regulate angiogenesis, similar to angiopoietins, whereas others have pleiotropic activity other than angiogenesis and function in lipid and energy metabolism. In this review, we focus on the roles of Angptl2 and Angptl6/angiopoietin-like growth factor (AGF) in the development of MetS and CVD, and discuss the potential for Angptl2 and Angptl6/AGF to function as molecular targets for the prevention and treatment of both conditions. (Circ J 2009; 73: 2192 -2197

show abstract

Identification of a novel human doublecortin-domain-containing gene (DCDC1) expressed mainly in testis

Cited by 36 publications

References 11 publications

Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans

Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans

Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation

Angiopoietin-Like Proteins Potential Therapeutic Targets for Metabolic Syndrome and Cardiovascular Disease

Contact Info

Product

Resources

About